<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03961919</url>
  </required_header>
  <id_info>
    <org_study_id>2008-000664-16</org_study_id>
    <nct_id>NCT03961919</nct_id>
  </id_info>
  <brief_title>Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant</brief_title>
  <acronym>FLAT-Auto</acronym>
  <official_title>Evaluation of Safety and Efficacy of Treosulfan-cytarabine-fludarabine (FLAT) Combination Prior to Autologous Stem Cell Transplant (HSCT) in Elderly Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ciceri Fabio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      FLAT-Auto is a phase II trial. fludarabine and ARA-C will be combined with the alkylating
      agent treosulfan (FLAT), to investigate the feasibility and the efficacy of a new regimen,
      supported with autologous peripheral blood SCT (PBSCT), as final postremission consolidation
      in AML/MDS elderly patients.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 10, 2009</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of disease free survival from first Complete Remission (CR)</measure>
    <time_frame>2 years after transplantation</time_frame>
    <description>Evaluation of disease-free survival (DFS) duration from documented first CR of AML or MDS with intermediate 2 or high IPSS (International Prognostic Score System).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Transplant-Related Hematologic Malignancy</condition>
  <arm_group>
    <arm_group_label>FLAT-Auto</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treosulfan in a combination regimen with ARA-C and fludarabine as conditioning therapy prior to autologous PBSCT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine i.v. 30 mg/m²/d day -6 to -2</description>
    <arm_group_label>FLAT-Auto</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARA-C</intervention_name>
    <description>Cytarabine i.v. 2 g/m²/d day -6 to -2</description>
    <arm_group_label>FLAT-Auto</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treosulfan</intervention_name>
    <description>Treosulfan i.v. 10 g/m²/d day -6 to -4</description>
    <arm_group_label>FLAT-Auto</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplant</intervention_name>
    <description>Autologous stem-cell transplantation i.v.: day 0 (source: peripheral blood)
Pegylated-Filgrastim s.c. 6 mg day +3</description>
    <arm_group_label>FLAT-Auto</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pts with de novo or secondary AML or with Int 2 or High risk MDS according to IPSS.

          -  Pts unable or unfit to receive SCT from an HLA (human leukocyte antigen)-identical
             related (SIB) or unrelated (MUD), or HLA-haploidentical related (HAPLO) donor.

          -  Hematologic CR (Appendix D) after 1 or 2 cycles of induction standard chemotherapy.

          -  Successful collection of autologous PBSC: ≥ 5.0x10e6 /kg patient bodyweight (BW)

          -  Age ≥ 65 years.

          -  Performance status 0-2 ECOG (Eastern Cooperative Oncology Group), 60-100% Karnofsky
             (Appendix E).

          -  Written informed consent.

        Exclusion Criteria:

          -  Diagnosis of AML M3.

          -  Second concomitant malignancies.

          -  Severe concomitant illnesses/medical conditions (e.g. impaired respiratory and/or
             cardiac function).

          -  Known and manifested malignant involvement of the central nervous system (CNS)

          -  Active infectious disease

          -  HIV- positivity or active hepatitis infection

          -  Impaired liver function (bilirubin &gt; 1.5 x upper normal limit; transaminases &gt; 3.0 x
             upper normal limit)

          -  Impaired renal function (creatinine-clearance &lt; 60 ml/min; serum creatinine &gt; 1.5 x
             upper normal limit).

          -  Known hypersensitivity to treosulfan and/or cytarabine and/or fludarabine

          -  Participation in another experimental drug trial within 4 weeks before day -6

          -  Non-cooperative behaviour or non-compliance

          -  Psychiatric diseases or conditions that might impair the ability to give informed
             consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 22, 2019</study_first_submitted>
  <study_first_submitted_qc>May 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2019</study_first_posted>
  <last_update_submitted>July 11, 2019</last_update_submitted>
  <last_update_submitted_qc>July 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Ciceri Fabio</investigator_full_name>
    <investigator_title>Head of Hematology and Translplant Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Treosulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

